LOS ANGELES--(BUSINESS WIRE)--Sera Labs, a subsidiary of CURE Pharmaceutical Holding Corp. (OTC: CURR), announced today a new ad campaign and launch of Seratopical Revolution, a new clean, plant-based, technologically advanced, anti-aging, ‘revolutionary,’ beauty line.
The line touts 11 luxurious products which are all are made in the U.S., available at accessible pricing, and are designed to make you feel more youthful and hydrated from head to toe. Award-winning actress Nicole Kidman, Sera Labs’ strategic business partner and global brand ambassador, collaborated with Sera Labs to design the Loving Hands Essential Oil, Indulgence Brown Sugar Scrub, Harmony Face & Neck Toner, and Gleaming for the ultimate brightening glow. The full line of products can be seen at Seratopicalrevolution.com.
“I really wanted to create something that was meaningful to me and that I knew people would genuinely enjoy,” said Kidman, Seratopical strategic business partner and global brand ambassador. “These products are personal to me from the scent to the texture. I am so excited to share them with the world and hope everyone loves them as much as we do.”
Seratopical Revolution marries nature and science into one clean and nourishing line of beauty products. The line’s PꝫP complex, developed by CURE Pharmaceutical, drives natural, plant-based ingredients into the deeper layers of the skin by utilizing a proprietary tri-peptide delivery system. Unlike other companies that use alcohol as a delivery system, which is incredibly drying to the skin, Seratopical Revolution’s natural oil and surfactant delivery systems are efficacious and offer almost immediate results.
“It’s been an incredible ride creating this line with Nicole,” said Nancy Duitch, Sera Labs CEO and CURE Pharmaceutical Chief Strategic Officer. “There are a lot of beauty companies, but the problem is that most of them don’t understand that without an effective delivery system, the products are sitting on top of your skin and clogging your pores. Our proprietary formulators have developed a high-tech delivery system which allows the ingredients to go deep into the skin. Our loyal customers will benefit from scientifically backed ingredients that are designed to enhance hydration and rejuvenate collagen. Revolution offers a full-body line packed with natural plant extracts and peptide blends.”
Seratopical Revolution products can be purchased online at seratopicalrevolution.com
Ad campaign photo and product images: https://www.dropbox.com/sh/o8l39o5xb0yj4bs/AAAj1WTWRwK05EpziP4BJn7ka?dl=0
About Sera Labs
Sera Labs® is a trusted leader in the health, wellness, and beauty sectors of innovative products with cutting edge technology and superior ingredients such as CBD and clean plant-based products. Sera Labs creates high quality products that use science-backed, proprietary formulations. Its more than 20 products are sold under the brand names Seratopical™, SeraLabs™, and Gordon’s Herbals™. Sera Labs sells its products at affordable prices, making them easily accessible on a global scale. Strategically positioned in the growth market categories of beauty, health & wellness. Sera Labs products are sold in major national drug, grocery chains and mass retailers. The company also sells products under private label to major retailers and multi-level marketers, as well as direct-to-consumer (DTC), via online website orders, including opt-in subscriptions. For more information visit: Seratopical.com, Seralabshealth.com and follow us on Instagram at @seratopical, as well as Twitter, and Facebook. Media contact: email@example.com.
About CURE Pharmaceutical Holding Corp.
CURE Pharmaceutical® is the pioneering developer of CUREform™, a patented drug delivery platform that offers a number of unique immediate- and controlled-release drug delivery vehicles designed to improve drug efficacy, safety, and patient experience for a wide range of active ingredients.
As a vertically integrated company, CURE’s 25,000 square foot, FDA-registered, NSF® cGMP-certified manufacturing facility enables it to partner with pharmaceutical and wellness companies worldwide for private and white-labeled production. CURE has partnerships in the U.S., China, Mexico, Canada, Israel, and other markets in Europe.
Forward Looking Statement
Statements CURE makes in this press release may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (“Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. CURE intends these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and is making this statement for purposes of complying with those safe harbor provisions.
These forward-looking statements include, without limitation, the ability to successfully market the partnered products, the difficulty in predicting the timing or outcome of related research and development efforts, partnered product characteristics and indications, marketing approvals and launches of other products, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing, the acceptance and demand of new pharmaceutical products, the impact of patents and other proprietary rights held by competitors and other third parties and the ability to obtain financing on favorable terms. The forward-looking statements in this press release reflect CURE’s judgment as of the date of this press release. CURE disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.